Canadian Active & Maintenance Modified Pentasa Study

Summary

The purpose of this study is to demonstrate that the new modified oral extended-release Pentasa® 500mg tablet is at least as efficacious as the currently marketed Pentasa® 500mg tablet in active mild to moderate Ulcerative Colitis (UC) and also in maintenance of quiescent disease.

Timeline

Start

2007-10

Primary completion

2011-05

Completion

2011-05

Drugs

Indications